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Abstract
Background: Intercellular communication can occur via the release of membrane vesicles. Exosomes are nanovesicles
released from the endosomal compartment of cells. Depending on their cell of origin and their cargo they can exert
different immunoregulatory functions. Recently, fungi were found to produce extracellular vesicles that can influence host-
microbe interactions. The yeast Malassezia sympodialis which belongs to our normal cutaneous microbial flora elicits specific
IgE- and T-cell reactivity in approximately 50% of adult patients with atopic eczema (AE). Whether exosomes or other
vesicles contribute to the inflammation has not yet been investigated.
Objective: To investigate if M. sympodialis can release nanovesicles and whether they or endogenous exosomes can
activate PBMC from AE patients sensitized to M. sympodialis.
Methods: Extracellular nanovesicles isolated from M. sympodialis, co-cultures of M. sympodialis and dendritic cells, and from
plasma of patients with AE and healthy controls (HC) were characterised using flow cytometry, sucrose gradient
centrifugation, Western blot and electron microscopy. Their ability to stimulate IL-4 and TNF-alpha responses in autologous
CD14, CD34 depleted PBMC was determined using ELISPOT and ELISA, respectively.
Results: We show for the first time that M. sympodialis releases extracellular vesicles carrying allergen. These vesicles can
induce IL-4 and TNF-a responses with a significantly higher IL-4 production in patients compared to HC. Exosomes from
dendritic cell and M. sympodialis co-cultures induced IL-4 and TNF-a responses in autologous CD14, CD34 depleted PBMC of
AE patients and HC while plasma exosomes induced TNF-a but not IL-4 in undepleted PBMC.
Conclusions: Extracellular vesicles from M. sympodialis, dendritic cells and plasma can contribute to cytokine responses in
CD14, CD34 depleted and undepleted PBMC of AE patients and HC. These novel observations have implications for
understanding host-microbe interactions in the pathogenesis of AE.
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Introduction
Exosomes are nanovesicles (30–100 nm) of endosomal origin
produced by different cells [1,2,3]. They can be secreted into the
extracellular space and act as means of intercellular communica-
tion by transferring functional proteins and RNA molecules
between cells [4,5]. They can also carry antigens from microor-
ganisms such as viruses and bacteria [6,7]. Exosomes can be
isolated from body fluids such as plasma [8], bronchoalveolar
lavage (BAL) fluid [9], breast milk [10] and urine [11]. Previous
studies have found that B-cells and dendritic cells (DC) release
MHC class II containing exosomes which could activate immune
responses in vitro and in vivo [12,13]. Due to their immunostimu-
latory capacity, exosomes from antigen presenting dendritic cells
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21480(APC) are currently being tested as vaccine vehicles in cancer
[14,15,16,17] and against infections [18,19]. However, it is still
unclear which role exosomes have in vivo and during human
inflammatory diseases. Only one previous study has investigated
the immunostimulatory effects of exosomes from cells of patients
with allergy. Here, B-cell exosomes directly loaded with birch
pollen allergen could induce Th2-cytokine responses in PBMC of
sensitised patients [20].
Atopic eczema (AE) is a common chronic inflammatory skin
disease. While the pathogenesis of the disease remains unclear,
studies suggest that a genetic predisposition in combination with
defects in the skin barrier facilitate the development of AE [21,22].
A defective skin barrier in turn might assist the entry of
microorganisms which can trigger symptoms by acting as allergens.
One such microorganism is the lipophilic yeast M. sympodialis, which
belongs to our common cutaneous microbial flora [23]. 30–80% of
adult AE patients are reactive to M. sympodialis in terms of specific
IgE- and T-cell reactivity and/or positive atopy patch test (APT)
reactions indicating a link between AE and M. sympodialis [24].
Sensitization to M. sympodialis is most likely mediated by APC such
as DC in the skin. We have previously found that human monocyte-
derived dendritic cells (MDDC) rapidly internalize M. sympodialis
[25] and in response upregulate the maturation marker CD83 and
the co-stimulatory molecules CD80 and CD86 [26]. Furthermore
M. sympodialis induces lymphocyte proliferation and a Th2-like
immune response in sensitized AE patients [27].
Recently, the release of extracellular vesicles has been described
for the fungi Cryptococcus neoformans, Histoplasma capsulatum and
Saccharomyces cerevisiae [28,29]. It is speculated that these vesicles
function in enzymatic nutrient degradation and in host-microbe
interactions [30], e.g. by modulating murine macrophage
functions in vitro [31].
In this study we hypothesised that M. sympodialis releases
nanovesicles with immune modulating functions. We compared their
capacity to induce cytokine responses in autologous PBMC of AE
patients and healthy controls (HC) with that of exosomes derived
from MDDC co-cultured with M. sympodialis or isolated from plasma.
We demonstrate for the first time that M. sympodialis releases
extracellular vesicles (MalaEx) carrying allergen. These vesicles
induced IL-4 and TNF-a responses in PBMC with a significantly
higher IL-4 production in the patients compared to the controls.
Furthermore, we report that exosomes from MDDC co-cultured with
M.sympodialis(DCexo Mala) elicit IL-4 and TNF-aresponses whereas
plasma exosomes induced TNF-a but not IL-4 production in AE
patients and HC. These novel findings suggest that nanovesicles,
autologous or derived from fungi, serve diverse immunoregulatory
functions which might contribute to the inflammation in AE.
Methods
Ethics Statement
The study was approved by the Regional Ethical Review Board
in Stockholm and all participants gave their written informed
consent.
AE patients and healthy controls
Male AE patients and HC (Table 1) were recruited from the
Stockholm area using the same inclusion and exclusion criteria as
Table 1. Characterisation of study subjects.
Individual
Age
(years)
Subjective
SCORAD
1)
Plasma IgE
(kU/L)
2) PhadiatopH,
3)
M.sympodialis specific
IgE (kU/L)
4)
HC
*1 25 - 22 Neg ,0.35
HC 2 57 - 6.5 Neg ,0.35
HC 3 63 - 8.7 Neg ,0.35
HC 4 25 - 11 Neg ,0.35
HC 5 22 - 14 Neg ,0.35
HC 6 43 - 6.9 Neg ,0.35
HC 7 41 - 8.5 Neg ,0.35
HC 8 24 - 35 Neg ,0.35
Median (range) 33 (22–63) 9.9 (6.5–35) ,0.35
AE
{1 25 65 140 Pos 0.83
AE 2 20 68 1600 Pos 25
AE 3 39 76 11000 Pos 27
AE 4 57 42 1400 Pos 21
AE 5 51 48 2200 Pos 29
AE 6 31 73 680 Pos 11
AE 7 21 62 120 Pos 1.6
AE 8 33 51 36 Pos 2.3
Median (range) 32 (20–57) 63.5 (42–76) 1040 (36–11000) 16 (1.6–29)
*HC=Healthy control.
{AE=Atopic eczema patient.
1)SCORAD = Severity scoring of atopic eczema [48].
2)ImmunoCAP
TM (Phadia AB), reference range 1.6–122 kU/L.
3)A positive PhadiatopH (Phadia AB) was defined as having plasma IgE to any of 11 common aeroallergens $0.35 kU/L.
4)Specific plasma IgE to M. sympodialis analysed with ImmunoCAP
TM (m70 Phadia AB).
All values (except SCORAD) were determined at the time of blood donation (AE 3 and 4 donated blood twice; values of the first donation are displayed).
doi:10.1371/journal.pone.0021480.t001
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controls were asked to come back for a full blood donation of
450 ml for generation of MDDC, storage of plasma at 280uC and
of PBMC at 2150uC. The blood donations and following
experiments were performed pairwise with one AE patient and
one HC. Twelve additional healthy blood donors were included
from the Karolinska University Hospital Solna Blood Bank.
Generation of monocyte derived dendritic cells (MDDC)
MDDC were generated as previously described [33] with some
modifications. PBMC were depleted of CD34
+ cells and CD14
+
monocytes by magnetic bead separation (Miltenyi Biotech,
Bergisch Gladbach, Germany) and the remaining cells were
frozen (CD14, CD34 depleted PBMC). CD14
+ monocytes were
cultured for 6 days in exosome-free medium [34] supplied with
1 ng/ml IL-4 (Biosource International, Camarillo, CA) and
10 ng/ml GM-CSF (Invitrogen/GIBCO, Paisley, UK) for differ-
entiation into MDDC. On day 6, cells were phenotyped by flow
cytometry (see below). The cells showed a typical phenotype of
immature MDDC as previously described [35] without any
significant differences between AE patients and HC (see Online
Repository S1).
Culture of M. sympodialis
M. sympodialis (ATCC strain 42132) was cultured on modified
Dixon agar plates [26] for 4 days at 32uC and contamination was
excluded using blood and Sab-oxoid agar plates. Colonies were
harvested and resuspended in RPMI-1640 (Hyclone, Logan, UT).
The cells were washed once and counted by the trypan blue
exclusion method. Supernatants from M. sympodialis cultured at a
concentration of 2610
6 cells/ml for 48 hr at 37uC in exosome-free
medium [34] were stored at 280uC for later nanovesicle
preparation.
Co-culture of MDDC with M. sympodialis
Immature MDDC were cultured with or without live M.
sympodialis. After 48 hr, culture supernatants were harvested and
kept at 280uC until exosome preparation and cells were
phenotyped using flow cytometry (see below and Online
Repository S1).
Flow cytometric analysis of cells
MDDC were phenotyped before and after culture with M.
sympodialis using flow cytometry and fluorescein-isothiocyanate
(FITC)- or phycoerythrin (PE)-labelled mouse monoclonal anti-
bodies (mAbs) using a FACS Calibur or FACS Aria (BDBios-
ciences, Bedford, MA) (see Online Repository S1).
Nanovesicle preparations
Nanovesicles from M. sympodialis culture supernatants, the
different MDDC culture supernatants and from plasma were
prepared by serial ultracentrifugation as described previously
[8,35] with slight modifications (see Online Repository S1). Pellets
were resuspended in PBS or RPMI, and protein content was
measured using a Bradford assay (BioRad, Hercules, CA) (Table
S1). Nanovesicle preparations were stored at 280uC.
Characterisation of nanovesicles
Exosomes were phenotyped on anti-MHC class II coated
Dynabeads (Invitrogen/Dynal, Paisley, UK) using mAbs and a
FACS Calibur (BDBiosciences) [20]. To verify the presence of
phenotypic cell markers or M. sympodialis antigens on vesicles,
sucrose gradient analysis was performed as previously described
[10] using uncoated latex beads (Invitrogen) or anti-MHC class II
Dynabeads (Invitrogen/Dynal) (see Online Repository S1).
Negative staining (TEM)
Three mL drops of DCexo, DCexo Mala or MalaEx samples
were added to carbon coated formvar grids for 10 min. The excess
solution was removed by a filter paper and grids were directly
stained by 2% uranyl acetate for 10 sec followed by a quick rinsing
in distilled water. Grids were analyzed in a Tecnai 12 transmission
electron microscope (FEI company, Eindhoven, The Netherlands)
and images were taken by a Veleta digital camera (Olympus Soft
Imaging Solutions, GmbH, Mu ¨nster, Germany).
Immuno-negative staining (iEM)
DCexo, DCexo Mala or MalaEx coated grids were blocked
from unspecific binding by floating grids face down on drops of
10% normal goat serum (NGS) in 0.1 M phosphate buffer (PB) for
10 min followed by incubation with a mAb against HLA-DR (BD
Biosciences) or a purified rabbit anti-M. sympodialis Ab (generated
in house) for 2 hr. As controls, the primary antibodies were
replaced by IgG2a (BDBiosciences) and normal rabbit IgG from
non-immunized mice (DAKO Cytomation, Glostrup, Denmark).
Grids were washed several times in phosphate buffer containing
0.1% NGS and bound antibodies were detected by secondary
gold-particle conjugated goat anti-rabbit (10 nm) and anti-mouse
(5 nm) (Biocell, BBInternational, Cardiff, England). Grids were
stained and analyzed as described above.
ELISPOT and ELISA analyses
CD14, CD34 depleted PBMC were cultured alone, or with
nanovesicles from M. sympodialis, or with exosomes from MDDC
cultured alone, or co-cultured with M. sympodialis at different
concentrationswhilePBMC were cultured with plasmaexosomes in
the absence or presence of M. sympodialis. IL-4 ELISPOT assays
were performed in triplicates for 48 hr according to the manufac-
turer’s instructions (Mabtech, Stockholm, Sweden) and analysed by
an ELISPOT automated reader (AID Diagnostika, Straßberg,
Germany) (seeOnlineRepositoryS1).ELISPOT supernatants were
harvested and analysed for TNF-a using ELISA according to the
manufacturer’s instructions (Mabtech). The detection limit was
8 pg/ml. Results are expressed as the mean of triplicates.
Western Blot
The pelleted sucrose gradient fractions from M. sympodialis
extracellular vesicles were denatured in Laemmli sample buffer
(BioRad), separated on SDS polyacrylamide gels (BioRad) and the
separated proteins were transferred to polyvinylidene difluoride
membrane(Millipore) using a semi dry blotting system (BioRad). M.
sympodialis specific bands were detected by using polyclonal rabbit
IgG raised against M. sympodialis extract (generated in house) in
1:2000 dilution, or serum from a patient with AE, sensitized to M.
sympodialis (M. sympodialis specific IgE (m70, Phadia AB) 39 kU/L,
total serum IgE 1700 kU/L) in a 1:5 dilution. Serum from HC no 6
(Table 1) was used as negative control. Antibodies used for detection
were rabbit anti-human IgE (1:2000, MIAB Antibodies, Uppsala,
Sweden) and horseradish peroxidase (HRP)-linked goat anti-rabbit
IgG (1:2000, Cell Signaling, Danvers, MA). Membranes were
developed using the enhanced chemiluminescence (ECL) advanced
detection kit (GE Healthcare).
Statistical analysis
Nonparametric tests were performed using Graphpad Prism
version 5 for Windows (Graphpad Software Inc., San Diego, CA,
Immunostimulatory Nanovesicles in Atopic Eczema
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within one group, and unpaired Mann-Whitney test between
groups. A p-value,0.05 was considered statistically significant.
Results
M. sympodialis secretes extracellular vesicles which elicit
IL-4 and TNF-a responses
We first cultured M. sympodialis alone to test whether the yeast
releases extracellular vesicles. Sucrose gradient fractions of pelleted
culture supernatants revealed the presence of M. sympodialis
derived antigens in density fractions ranging from 1.10 to
1.20 g/ml using flow cytometry (Fig. 1A). TEM analysis of these
fractions showed the presence of vesicular structures with a size
between 50–200 nm, with an average of approximately 100 nm
(Fig. 1B). When performing iEM we could locate M. sympodialis
antigens on these vesicular structures while controls showed
negligible and unspecific labelling (Fig. 1C). Western blot analysis
of the sucrose gradient fractions using polyclonal rabbit IgG raised
against M. sympodialis showed the presence of antigens in vesicle
fractions ranging in density from 1.12 g/ml to 1.22 g/ml (Fig. 1D)
and 1.10–1.21 g/ml in two independent experiments, respectively.
We then continued to look for IgE-binding epitopes using a
separate sucrose gradient. When using serum from an AE patient
Figure 1. M. sympodialis releases extracellular vesicles. (A) M. sympodialis culture supernatants were ultracentrifuged and sucrose gradient
fractions coated onto latex beads and analysed for the presence of M. sympodialis epitopes using flow cytometry. Data is from one representative out
of 6 independent experiments and displayed as mean MFI ratio of a rabbit antibody against M. sympodialis and unspecific rabbit IgG. Fractions
ranging in density from 1.11–1.20 g/ml were pooled and analysed by (B) TEM and (C) IEM with the same antibody as in A. Scale bars correspond to
100 nm. Pictures are representative in (B) of 4 independent experiments and in (C) of two independent experiments. (D) Western blot analysis of
sucrose gradient fractions analysed using a rabbit antibody against M. sympodialis and (E) using serum from an AE patient sensitized to M.
sympodialis to detect IgE-binding epitopes. Data shown in (D) and (E) are from one out of 2 experiments using separate sucrose gradients.
doi:10.1371/journal.pone.0021480.g001
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IgE-binding protein with a size of approximately 70 kDa in
fractions ranging in density between 1.10–1.18 g/ml (Fig. 1E) in
two independent experiments. No bands were detected when using
serum of HC no 6 (Table 1, data not shown). Thus, M. sympodialis
can produce nanovesicles which contain antigens and among those
also allergen.
Next we assessed the effect of M. sympodialis vesicles, designated
MalaEx, on CD14, CD34 depleted PBMC from AE patients and
HC in an IL-4 ELISPOT assay for 48 hr. MalaEx significantly
enhanced IL-4 production in CD14, CD34 depleted PBMC
compared to the medium control in a dose dependent manner
(Fig. 2A). The IL-4 responses were significantly higher in AE
patients compared to HC both for MalaEx and for whole M.
sympodialis cells (Mala) used as a control. MalaEx also induced a
dose dependent TNF-a response in both AE patients and HC but
without any significant differences between the two groups
(Fig. 2B). These data indicate that M. sympodialis derived vesicles
can elicit cytokine responses and that there is a difference in IL-4
reponse to MalaEx between HC and AE patients.
Exosomes from MDDC and M. sympodialis co-cultures
contain M. sympodialis antigens
Since DCs are among the first cells to encounter M. sympodialis
in the skin, we prepared vesicles from MDDC and M. sympodialis
co-cultures (DCexo Mala) and from MDDC alone (DCexo) to
investigate the possible presence of M. sympodialis antigens on
endogenous exosomes.
In agreement with a previous study, M. sympodialis induced
maturation of MDDC, with a significant upregulation of CD80,
CD83 and CD86 on MDDC [26], with no significant differences
between AE patients and HC (Figure S1). M. sympodialis did not
induce significant differences in the other molecules investigated
(HLA-ABC, HLA-DR, CD11c, CD14, CD40, CD54 and CD63)
compared to the medium control (data not shown).
Flow cytometry analysis of sucrose gradient fractionated vesicles
revealed the presence of HLA-DR and the tetraspanin CD63 in
DCexo and DCexo Mala in fractions corresponding to exosomes
(density 1.11–1.20 g/ml, [12], Fig. 3A). We could also detect M.
sympodialis epitopes in sucrose gradient fractions of DCexo Mala
ranging in density from 1.11–1.20 g/ml using flow cytometry, but
not in the corresponding fractions of DCexo (Fig. 3B). Double
iEM with a mAb to HLA-DR and a rabbit antibody to M.
sympodialis revealed the presence of double positive vesicles in
DCexo Mala preparations while the majority of the DCexo only
bound the anti-HLA-DR antibody. Vesicles in MalaEx prepara-
tions only bound the antibody against M. sympodialis while isotype
IgG controls showed negligible labelling (Fig. 3C).
Exosomes from MDDC and M. sympodialis co-cultures
induce IL-4 and TNF-a responses
To test whether endogenous nanovesicles have similar effects on
cytokine responses as exogenous MalaEx, we added DCexo Mala
in an IL-4 ELISPOT assay. We found that DCexo Mala induced
significantly higher IL-4 responses than DCexo in autologous
CD14, CD34 depleted PBMC from AE patients but not in CD14,
CD34 depleted PBMC from HC (Fig. 4A). IL-4 responses were
highest in response to M. sympodialis whole cells (Mala) and MDDC
co-cultured with M. sympodialis (DCMala) with a statistically
significant induction of IL-4 also in the HC group compared to the
medium control (Fig. 4A). However, the levels were significantly
lower than those observed in the AE patients. The TNF-a levels
were significantly increased when stimulating CD14, CD34
depleted PBMC with DCexo Mala compared to DCexo in AE
patients (Fig. 4B). A similar trend was seen for HC (Fig. 4B, C).
To investigate whether TNF-a induction indeed was due to
DC-derived vesicles, exosome preparations from two additional
healthy blood donors were depleted of MHC class II containing
vesicles using anti-MHC class II Dynabeads. The DCexo Mala
induced TNF-a levels were decreased by 38% (donor A) or 52%
Figure 2. MalaEx elicit IL-4 and TNF-a responses. (A) IL-4 production in CD14, CD34 depleted PBMC as measured by ELISPOT from HC and AE
patients when cultured alone (medium) or with MalaEx or M. sympodialis (Mala) for 48 hr. (B) TNF-a levels in the IL-4 ELISPOT supernatants were
measured by ELISA. Data represent mean values of triplicates for each individual (Table 1); lines indicate median.
doi:10.1371/journal.pone.0021480.g002
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M. sympodialis (DCexo Mala) were analysed for the expression of HLA-DR and CD63 using flow cytometry. Data are representative for one out of 3
experiments each using a pool of exosomes from 2 healthy blood donors and displayed as MFI ratio between specific antibody and isotype control.
(B) Sucrose gradient fractions of DCexo and DCexo Mala analysed using flow cytometry. Data are from 5 independent experiments and displayed as
mean MFI ratio 6 SEM between a rabbit antibody against M. sympodialis and unspecific rabbit IgG. (C) Double IEM was performed on pools of DCexo
and DCexo Mala from 5 AE patients and 3 HC as well as 2 independent preparations of MalaEx using a mAb against HLA-DR (detected with a 5 nm
gold-particle conjugated goat anti-mouse Ab, white arrows) and a rabbit antibody against M. sympodialis (detected with a 10 nm gold-particle
conjugated goat anti-rabbit Ab, black arrows) and the corresponding isotype controls. Scale bars correspond to 100 nm.
doi:10.1371/journal.pone.0021480.g003
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at least in part due to DC-derived exosomes from the co-cultures.
Plasma exosomes elicit TNF-a but not IL-4 in autologous
PBMC
Finally we prepared nanovesicles from plasma to find out
whether their phenotype or function differed between AE patients
and HC. Sucrose gradient analysis of plasma exosomes revealed
the presence of CD81 and HLA-DR in density fractions ranging
from 1.10 to 1.18 g/ml (Fig. 5A). Phenotypic analysis showed the
presence of HLA-ABC, HLA-DR, CD54, CD63, and CD81 on
plasma exosomes without any significant differences between AE
patients and HC (Fig. 5B) while neither CD3, CD19, CD86, FasL,
the B-cell activating factor of the TNF-family (BAFF) nor TGFb1
could be detected on plasma exosomes (data not shown).
To assess whether these plasma exosomes could elicit cytokine
responses they were added to autologous PBMC. In addition, we
added M. sympodialis to the assay to see whether plasma exosomes
could suppress or potentiate the immune response as seen in
murine models of allergic sensitisation and delayed-type hyper-
sensitivity [36,37]. Plasma exosomes alone could neither elicit nor
inhibit IL-4 responses in PBMC in any of the two groups at a
concentration of 10 mg/ml (Fig. 5C). However, plasma exosomes
as well as whole yeast cells significantly increased TNF-a
production in PBMC of both AE patients and HC compared to
the medium control and plasma exosomes enhanced the M.
sympodialis induced TNF-a response in AE patients (Fig. 5D).
These data suggest that plasma exosomes can contribute to innate
immune responses in both AE patients and healthy controls.
Discussion
Studies on the role of exosomes in human diseases are still
hampered by the difficulties to isolate enough exosomes for
functional studies in combination with their small size requiring
demanding special techniques for their characterization [34]. We
were here fortunate to obtain a full blood donation from the
participants. Our study provides new insights into host-microbe
interactions between a fungi and cells of our immune system. We
found that exosomes from DCs co-cultured with M. sympodialis
(DCexo Mala) carried M. sympodialis antigens and could stimulate
cytokine production in autologous CD14, CD34 depleted PBMC
from AE patients and HC. Furthermore, we show for the first time
that M. sympodialis, a commensal yeast associated with AE [21,24],
secretes extracellular vesicles (MalaEx). These nanovesicles
Figure 4. DCexo Mala elicit IL-4 and TNF-a responses. (A) IL-4 production in autologous CD14, CD34 depleted PBMC from AE patients and HC
as measured by ELISPOT when cultured alone (medium), with DCexo, DCexo Mala, M. sympodialis (Mala) or MDDC co-cultured with M. sympodialis
(DCMala) for 48 hr. (B) TNF-a levels in the IL-4 ELISPOT supernatants were measured by ELISA. Data represent mean values of triplicates for each
individual (Table 1); lines indicate median. (C) TNF-a levels in supernatants of CD14, CD34 depleted PBMC of two additional healthy blood donors (HC
A and HC B) when cultured alone (un), with DCexo or DCexo Mala (Exo) or with DCexo and DCexo Mala that were depleted of MHC class II positive
vesicles (depl. Exo). Bars indicate mean value of duplicates.
doi:10.1371/journal.pone.0021480.g004
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cytokine responses in CD14, CD34 depleted PBMC of AE patients
and HC with a significantly higher IL-4 response in the M.
sympodialis sensitized patients. The variation in IL-4 production
between patients is in line with our previous study using extract of
whole M. sympodialis cells [32]. Similar variation in cytokine
responses in culture supernatants of PBMC stimulated with
recombinant birch allergen, measured by cytometric bead array,
has been reported for patients sensitised to birch pollen [38]. Our
data suggest that extracellular vesicles, whether derived from M.
sympodialis or from APC exposed to the fungi, may have a role in
the pathogenesis of AE.
It has previously been shown that host exosomes can carry
antigens from viruses and bacteria [6,7] Exosomes from murine
macrophages infected with intracellular pathogens have been
found to contain pathogen associated molecular patterns (PAMPs)
which could elicit pro-inflammatory responses in vitro and in vivo
[6]. In case of infection with Mycobacterium avium, bacterial
glycopeptidolipids could be traced through the endosomal
compartment and were found in multivesicular bodies (MVBs)
and on exosomes [39]. In analogy with this, M. sympodialis antigens
might be processed by DCs and released on DC-derived exosomes
which then induce cytokine responses.
With three different techniques we found M. sympodialis derived
epitopes on MalaEx in vesicle containing sucrose gradient
fractions ranging in density between 1.10–1.22 g/ml (Fig. 1A, D
and E). By using patient serum we could detect an IgE-binding
epitope with a size of approximately 70 kDa on MalaEx (Fig. 1E).
Several IgE binding components in the 10–100 kDa molecular
weight range have been identified in Malassezia and so far 10 M.
sympodialis allergens have been cloned and sequenced (www.
allergen.org, [24]). Thus, the observation that extracellular vesicles
released by the yeast cells carry antigens and allergen and have the
capacity to activate CD14, CD34 depleted PBMC raises questions
on their role in the sensitization process and maintenance of the
inflammatory response in AE. The nanovesicles are much smaller
in size compared to whole yeast cells, which might lead to a
different dissemination in the host and involve other mechanisms
of cellular uptake and cell targeting. MalaEx were more potent
than DCexo Mala to induce immune responses (cf Figs 2 and 4,
and Table S2) which is why we speculate that MalaEx accumulate
immunogenic molecules on their surface to enhance host-microbe
Figure 5. Plasma exosomes elicit TNF-a but not IL-4 responses. (A) Sucrose gradient fractions of plasma exosomes pooled from 2 healthy
blood donors were loaded onto anti-MHC class II Dynabeads and analysed for the presence of HLA-DR and CD81 using flow cytometry. MFI ratio was
calculated by dividing the sample MFI by the isotype control MFI. Data are from one out of two experiments. (B) plasma exosomes isolated from HC
and AE patients were loaded onto anti-MHC class II Dynabeads and phenotyped using flow cytometry. Lines indicate the median. (C) PBMC were
either cultured in only medium in the absence (2) or presence (+)o fM. sympodialis or with autologous plasma exosomes in the absence (2)o r
presence (+)o fM. sympodialis. IL-4 production in PBMC were measured by ELISPOT. (D) Culture supernatants from (C) were analysed for TNF-a levels
using ELISA. Data represent mean values of triplicates for each individual (Table 1); lines indicate median.
doi:10.1371/journal.pone.0021480.g005
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the surface of vesicles compared to that of yeast cells could lead to
altered allergenicity. Interestingly, the elevated pH of AE skin [40]
can induce an enhanced allergen release from M. sympodialis [41].
Future studies will show if altered pH will stimulate the production
and allergenicity of Malassezia nanovesicles.
MalaEx and DCexo Mala also induced TNF-a responses in AE
patients and HC. No statistically significant difference in TNF-a
production were detected between AE patients and HC in
response to any stimuli used (Table S2). It has previously been
reported that M. sympodialis cells as well as the allergen Mala s 11
induce TNF-a production in MDDC and PBMC of healthy
subjects [26,42,43]. This suggests that the TNF-a response is
independent of previous sensitisation to M. sympodialis and
represents an innate immune response. Our preliminary results
indicate that TNF-a production in response to M. sympodialis or
MalaEx involves NK-cells and possibly cd-T-cells since an
upregulation of the activation marker CD69 was seen on these
cells (Gehrmann U. et al, unpublished observations).
It is reasonable to assume that exosomes from the host and
extracellular vesicles from M. sympodialis coexist in vivo and
contribute to host-microbe interactions. This might also be the
case in our in vitro co-culture system. However, we believe that
most of the immune responses recorded with DCexo Mala are
induced by the exosomes from the DC and not the yeast for the
following reasons: First, using iEM we found that the vast majority
of vesicles in the DCexo Mala preparations were HLA-DR
positive indicating their DC origin. Secondly, we have previously
found that MDDC rapidly phagocytose live M. sympodialis cells
within the first hr of culture [25] and we observed only few M.
sympodialis cells in the medium after 48 hr of co-culture with
MDDC using light microscopy (data not shown). Thirdly, by
partially removing HLA-DR expressing DCexo Mala the TNF-a
response was reduced by 40–50% (Fig. 3D). Due to limited
amounts of exosomes we could not titrate the depletion with MHC
class II beads but with a full titration an even stronger inhibition
might have been seen.
Finally, we asked whether exosomes isolated from plasma could
induce cytokine responses in PBMC. Human plasma exosomes are
today mainly investigated as diagnostic markers for neoplastic
diseases [44] and very little is known about the immunostimulatory
or suppressive capacities of plasma exosomes. We found that
plasma exosomes alone had no significant effect on IL-4
production indicating that they were not able to activate or
suppress M. sympodialis specific responses. This might either be due
to the absence of M. sympodialis antigens on plasma exosomes or to
a small number of antigen-bearing plasma exosomes. Interestingly,
plasma exosomes could induce TNF-a production in PBMC of
both AE patients and HC (Fig. 5D) This induction could be due to
the presence of PAMPs on exosomes, alternatively, pre-formed
mRNA or mRNA stabilizing molecules for TNF-a [45]. One
possible interpretation of these results is that plasma exosomes
circulate as mediators capable of inducing a pro-inflammatory
response when reaching high concentrations e.g. in local
inflammatory settings. Since plasma exosomes contain leukotriene
producing enzymes [46] the formation of pro-inflammatory lipid
mediators and production of TNF-a might coincide and
contribute to local inflammation. The capacity to induce TNF-a
production has also been shown for other exosomes such as
melanoma derived exosomes [47]. Although coming from
different sources, the underlying mechanism for TNF-a induction
might be similar for both types of exosomes.
In summary, we here present novel data that a microorganism
releases extracellular vesicles that contain allergen and can
contribute to inflammatory cytokine responses. This study also
suggests that exosomes from DCs exposed to M. sympodialis can
elicit IL-4 and TNF-a responses while plasma exosomes might be
able to contribute to inflammation by inducing TNF-a. These
observations have implications for understanding host-microbe
interactions in the sensitisation and maintenance of the inflam-
mation in AE.
Supporting Information
Figure S1 M. sympodialis induces maturation in MDDC.
Phenotypes of MDDC generated from AE patients and HC
assessed by flow cytometry after 48 hr culture without (2) or with
(+) M. sympodialis in a 1:5 ratio. Data show median of mean
fluorescence intensity (MFI) of the sample divided by the isotyope
control, 25th–75th percentile and range.
(TIF)
Table S1 Protein content
1) of vesicle preparations. *
HC=Healthy control. { AE=Atopic eczema patient.
1)as
determined by Bradford assay (BioRad, Hercules, CA).
2)Exo-
somes were resuspended in RPMI.
3)Exosomes were resuspended
in PBS.
(PPT)
Table S2 Exosome-induced cytokine responses in AE
patients and healthy controls. 1 HC=Healthy control. {
AE=Atopic eczema patient. ND=not done.
1)as determined by
ELISPOT.
2)as determined by ELISA. *Mann-Whitney test to
compare AE and HC, p-value,0.05.
(PPT)
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